Loading...
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
Patients with type 2 diabetes mellitus (T2DM) appear to have increased risk for fractures. In this context, the finding that canagliflozin, a sodium-glucose co-transporter-2 (SGLT) inhibitor, increased the risk for fracture compared with placebo in the Canagliflozin Cardiovascular Assessment Study (...
Saved in:
| Published in: | Diabetes Ther |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Springer Healthcare
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6965547/ https://ncbi.nlm.nih.gov/pubmed/31734830 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00724-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|